Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study

Background Despite simpler regimens than vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF), adherence (taking drugs as prescribed) and persistence (continuation of drugs) to direct oral anticoagulants are suboptimal, yet understudied in electronic health records (EHRs). Objective We investigated (1) time trends at individual and system levels, and (2) the risk factors for and associations between adherence and persistence. Methods In UK primary care EHR (The Health Information Network 2011–2016), we investigated adherence and persistence at 1 year for oral anticoagulants (OACs) in adults with incident AF. Baseline characteristics were analysed by OAC and adherence/persistence status. Risk factors for non-adherence and non-persistence were assessed using Cox and logistic regression. Patterns of adherence and persistence were analysed. Results Among 36 652 individuals with incident AF, cardiovascular comorbidities (median CHA2DS2VASc[Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65-74 years, Sex category] 3) and polypharmacy (median number of drugs 6) were common. Adherence was 55.2% (95% CI 54.6 to 55.7), 51.2% (95% CI 50.6 to 51.8), 66.5% (95% CI 63.7 to 69.2), 63.1% (95% CI 61.8 to 64.4) and 64.7% (95% CI 63.2 to 66.1) for all OACs, VKA, dabigatran, rivaroxaban and apixaban. One-year persistence was 65.9% (95% CI 65.4 to 66.5), 63.4% (95% CI 62.8 to 64.0), 61.4% (95% CI 58.3 to 64.2), 72.3% (95% CI 70.9 to 73.7) and 78.7% (95% CI 77.1 to 80.1) for all OACs, VKA, dabigatran, rivaroxaban and apixaban. Risk of non-adherence and non-persistence increased over time at individual and system levels. Increasing comorbidity was associated with reduced risk of non-adherence and non-persistence across all OACs. Overall rates of ‘primary non-adherence’ (stopping after first prescription), ‘non-adherent non-persistence’ and ‘persistent adherence’ were 3.5%, 26.5% and 40.2%, differing across OACs. Conclusions Adherence and persistence to OACs are low at 1 year with heterogeneity across drugs and over time at individual and system levels. Better understanding of contributory factors will inform interventions to improve adherence and persistence across OACs in individuals and populations.

[1]  R. Ofori-Asenso,et al.  Predictors of first‐year nonadherence and discontinuation of statins among older adults: a retrospective cohort study , 2018, British journal of clinical pharmacology.

[2]  A. Wu,et al.  Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010–2017 , 2018, Pharmacotherapy.

[3]  T. Marshall,et al.  Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016 , 2018, Heart.

[4]  E. Hagström,et al.  A systematic literature review comparing methods for the measurement of patient persistence and adherence , 2018, Current medical research and opinion.

[5]  M. Lemstra,et al.  Primary nonadherence to chronic disease medications: a meta-analysis , 2018, Patient preference and adherence.

[6]  J. Segal,et al.  Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017 , 2018 .

[7]  S. Peiró,et al.  Primary Nonadherence to Oral Anticoagulants in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort , 2018, Journal of managed care & specialty pharmacy.

[8]  Fernando Fernandez-Llimos,et al.  Economic impact of medication non-adherence by disease groups: a systematic review , 2018, BMJ Open.

[9]  M. Pastorello,et al.  Non-persistence risk and health care resource utilization of Italian patients with non-valvular atrial fibrillation , 2017, Recenti progressi in medicina.

[10]  L. Sharp,et al.  Real‐World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation , 2017, Pharmacotherapy.

[11]  G. Lip,et al.  Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation. , 2017, Journal of the American College of Cardiology.

[12]  L. Huiart,et al.  Trends in the prescription of novel oral anticoagulants in UK primary care , 2017, British journal of clinical pharmacology.

[13]  M. Bennie,et al.  Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies , 2017, Pharmacoepidemiology and drug safety.

[14]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[15]  M. Turakhia,et al.  Get With The Guidelines AFIB: Novel Quality Improvement Registry for Hospitalized Patients With Atrial Fibrillation , 2014, Circulation. Cardiovascular quality and outcomes.

[16]  G. Lip,et al.  Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria , 2014, PloS one.

[17]  George A Mensah,et al.  Global burden of atrial fibrillation in developed and developing nations. , 2014, Global heart.

[18]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[19]  J. Steiner,et al.  Standardizing Terminology and Definitions of Medication Adherence and Persistence in Research Employing Electronic Databases , 2013, Medical care.

[20]  Paulus Kirchhof,et al.  Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhyt , 2013, European heart journal.

[21]  Jeffrey K Aronson,et al.  A new taxonomy for describing and defining adherence to medications. , 2012, British journal of clinical pharmacology.

[22]  J. Ioannidis,et al.  STrengthening the Reporting of OBservational studies in Epidemiology – Molecular Epidemiology (STROBE-ME): An Extension of the STROBE Statement , 2011, PLoS medicine.

[23]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[24]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[25]  A. Bourke,et al.  Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. , 2011, Informatics in primary care.

[26]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[27]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[28]  D. S. Houston,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[29]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[30]  Bradley C Martin,et al.  Good and poor adherence: optimal cut-point for adherence measures using administrative claims data , 2009, Current medical research and opinion.

[31]  Morris J. Brown.  A RATIONAL BASIS FOR SELECTION AMONG DRUGS OF THE SAME CLASS , 2003, Heart.

[32]  D K Owens,et al.  Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. , 1995, JAMA.

[33]  Paolo Vineis,et al.  STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement. , 2011, Preventive medicine.